FimmCyte AG develops targeted immunotherapies for fibro-inflammatory diseases, with a primary focus on endometriosis and women’s health. The company is working on disease-modifying treatments designed to address diseased tissue while preserving healthy tissue.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Targeted immunotherapies for fibro-inflammatory diseases, especially endometriosis; non-hormonal, disease-modifying approaches focused on fibrotic tissue and gentler treatment.
Endometriosis Therapies
Non-hormonal, disease-modifying therapies for endometriosis focused on inflammation, fibrosis, lesion growth and longer-term disease control.
Fibro-Inflammatory Disease Therapies
Therapies for other fibro-inflammatory diseases, with pipeline candidates for chronic fibrotic conditions beyond endometriosis.
Patient Information and Endometriosis Resources
Patient information on endometriosis, treatment approaches and further support resources, with links to external information and peer-support organisations.
Comparisons
FimmCyte AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank FimmCyte AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once FimmCyte AG has claimed this profile, we'll publish editorial articles and case studies here together.